Bernstein: Kelun-Biotech lung cancer data update: first-line treatment delays progression, later-line survival benefit persists
sac-TMT significantly prolonged progression-free survival in difficult-to-treat PD-L1-negative first-line lung cancer, while a later-line study also confirmed an overall survival advantage. Bernstein sees these results supporting expansion of its treatment scope, but first-line overall survival data remain immature, and the relative benefit in later-line treatment narrowed compared with the interim analysis.